SBTX — Skinbiotherapeutics Balance Sheet
0.000.00%
- £40.11m
- £39.90m
- £1.21m
Annual balance sheet for Skinbiotherapeutics, fiscal year end - June 30th, GBP millions except per share, conversion factor applied.
2020 June 30th | R2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | Interim Report | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 2.16 | 4.61 | 1.8 | 1.31 | 0.801 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.141 | 0.453 | 0.405 | 0.375 | 0.341 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 2.35 | 5.06 | 2.33 | 1.72 | 1.67 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.002 | 0.143 | 0.127 | 0.173 | 0.116 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Total Assets | 2.77 | 5.73 | 3.08 | 2.59 | 5.22 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 0.305 | 0.405 | 0.509 | 0.53 | 1.8 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 0.305 | 0.52 | 0.61 | 0.599 | 2.25 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 2.47 | 5.22 | 2.48 | 1.99 | 2.97 |
| Total Liabilities & Shareholders' Equity | 2.77 | 5.73 | 3.08 | 2.59 | 5.22 |
| Total Common Shares Outstanding |